Laura Cinski, MD
Neurology · Fairfax, VANPI 1003006198
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,552 of the $122,396 with a category attached, or 86.2%. 24 manufacturers reported payments, led by AbbVie at 56.9% of the total. 2025 is the largest year on record at $52,000, more than ten times the $1,052 reported in 2019. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $365.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$70K
- Pfizer$14K
- Biohaven Pharmaceuticals, Inc.$13K
- Biohaven Pharmaceutical Holding Company Ltd.$11K
- Lilly USA, LLC$6K
- Axsome Therapeutics, Inc.$4K
- plus $5K from 18 others
Across 13 payments — averaging $115.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$2K
What the payments were for
- Consulting fees$5,7285%
- Speaking & faculty fees$105,55286%
- Travel & lodging$3,3023%
- Food & beverage$7,8006%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 190 | $69,700 |
| Pfizer | 15 | $14,294 |
| Biohaven Pharmaceuticals, Inc. | 24 | $12,606 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $10,838 |
| Lilly USA, LLC | 18 | $5,843 |
| Axsome Therapeutics, Inc. | 4 | $4,165 |
| Lundbeck LLC | 14 | $3,254 |
| Amgen | 7 | $416 |
| Supernus Pharmaceuticals, Inc. | 12 | $275 |
| Novartis | 15 | $269 |
| Sunovion Pharmaceuticals Inc. | 7 | $226 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| AstraZeneca | 1 | $116 |
| Impel Pharmaceuticals Inc. | 2 | $37 |
| Acorda Therapeutics, Inc | 2 | $36 |
| UCB, Inc. | 1 | $35 |
| Impel Pharmaceuticals LLC | 1 | $25 |
| SK Life Science, Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,396 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 117 | $213,957 |
| QuliptaAtogepant | 159 | $195,083 |
| UbrelvyUbrogepant | 78 | $124,585 |
| Aimovig AutoinjectorErenumab-Aooe | 63 | $67,516 |
| Emgality PenGalcanezumab-Gnlm | 50 | $36,112 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $20,068 |
| Ergotamine-CaffeineErgotamine Tartrate/Caffeine | 12 | $2,860 |
| RizatriptanRizatriptan Benzoate | 112 | $2,073 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 61 | $1,562 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 26 | $1,471 |
| Gabapentin | 121 | $1,010 |
| Topiramate | 64 | $799 |
| Sumatriptan Succinate | 37 | $677 |
| Duloxetine Hcl | 38 | $652 |
| Pregabalin | 18 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $69,700 | $319,668237 claims |
| PfizerNurtec Odt | $14,294 | $213,957117 claims |
| Upsher-smith Laboratories LLCTopiramate | $19 | $79964 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Fairfax
- Rahul DaveFairfax$540K
- John RothrockFairfax$225K
- James SimsarianFairfax$173K
- Abigail LawlerFairfax$107K
- Amy StoneFairfax$70K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.